Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Plato Investment Management Ltd

Key Points

• Plato Investment Management Ltd reduced its holdings in Alnylam Pharmaceuticals by 16.0%, selling 888 shares and leaving them with 4,659 shares valued at approximately $1.27 million.
• Insider sales included Director Michael W. Bonney selling 11,250 shares for $5.06 million and CEO Yvonne Greenstreet selling 6,979 shares for $3.16 million, both reflecting notable decreases in their ownership stakes.
• Alnylam Pharmaceuticals recently reported better-than-expected quarterly earnings, with an EPS of $0.32, significantly above the analysts' consensus estimate of -$0.54, and a revenue of $773.69 million, up 17.3% year-over-year.

Plato Investment Management Ltd reduced its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 16.0% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 4,659 shares of the biopharmaceutical company's stock after selling 888 shares during the quarter. Plato Investment Management Ltd's holdings in Alnylam Pharmaceuticals were worth $1,272,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. SVB Wealth LLC bought a new position in Alnylam Pharmaceuticals in the first quarter worth about $27,000. Park Square Financial Group LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $28,000. Whipplewood Advisors LLC boosted its position in Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 71 shares during the period. Bessemer Group Inc. grew its stake in Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 69 shares during the last quarter. Finally, Washington Trust Advisors Inc. increased its position in Alnylam Pharmaceuticals by 53.5% in the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock worth $47,000 after buying an additional 61 shares during the period. Institutional investors own 92.97% of the company's stock.

Insider Transactions at Alnylam Pharmaceuticals

In related news, Director Michael W. Bonney sold 11,250 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $450.00, for a total transaction of $5,062,500.00. Following the completion of the sale, the director directly owned 16,804 shares of the company's stock, valued at $7,561,800. This represents a 40.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Yvonne Greenstreet sold 6,979 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $453.27, for a total transaction of $3,163,371.33. Following the sale, the chief executive officer owned 56,221 shares of the company's stock, valued at $25,483,292.67. The trade was a 11.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 57,594 shares of company stock valued at $25,551,456 in the last quarter. 1.50% of the stock is owned by company insiders.

Analyst Ratings Changes

ALNY has been the subject of several recent research reports. Wolfe Research upgraded shares of Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a research report on Monday, August 4th. Scotiabank upped their target price on shares of Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a "sector outperform" rating in a research report on Friday, August 1st. Citigroup lifted their price target on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a "buy" rating in a report on Tuesday, September 2nd. Chardan Capital increased their price objective on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Finally, Raymond James Financial initiated coverage on Alnylam Pharmaceuticals in a research report on Wednesday, July 30th. They issued an "outperform" rating and a $370.00 target price on the stock. Twenty-two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $417.38.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $469.31 on Thursday. The business has a 50 day moving average price of $396.04 and a two-hundred day moving average price of $313.80. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The company has a market capitalization of $61.52 billion, a price-to-earnings ratio of -190.00 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. The company had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company's quarterly revenue was up 17.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.